Currently out of the existing stock ratings of Brian Abrahams, 341 are a HOLD (40.36%), 499 are a BUY (59.05%), 5 are a SELL (0.59%).

Brian Abrahams

Work Performance Price Targets & Ratings Chart

Analyst Brian Abrahams, currently employed at RBC, carries an average stock price target met ratio of 45% that have a potential upside of 31.61% achieved within 198 days.

Brian Abrahams’s has documented 1,639 price targets and ratings displayed on 53 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on PTCT, PTC Therapeutics at 20-Feb-2026.

Wall Street Analyst Brian Abrahams

Analyst best performing recommendations are on CDTX (CIDARA THERAPEUTICS).
The best stock recommendation documented was for CDTX (CIDARA THERAPEUTICS) at 11/7/2025. The price target of $145 was fulfilled within 7 days with a profit of $40.61 (38.9%) receiving and performance score of 55.57.

Average potential price target upside

of $105.28 (14.16%) on REGN (REGENERON PHARMACEUTICALS).
of $41.64 (25.67%) on KRTX (KARUNA THERAPEUTICS).
of $41.32 (48.09%) on SRPT (SAREPTA THERAPEUTICS).

ATAI ATAI Life Sciences BV BIIB Biogen CELG Celgene DVAX Dynavax Technologies ENTA Enanta Pharmaceuticals ETN Eaton PLC GILD Gilead Sciences GLPG Galapagos NV ADR HOOK Hookipa Pharma ICPT Intercept Pharmaceuticals INCY yte ITCI Intracellular Th KPTI Karyopharm Therapeutics KRTX Karuna Therapeutics MRUS Merus BV NBIX Neurocrine Biosciences OVID Ovid Therapeutics PLRX Pliant Therapeutics PTCT PTC Therapeutics SAGE Sage Therapeutic SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals CNST Constellation Pharmaceuticals IGMS IGM Biosciences BCRX BioCryst Pharmaceuticals ALDR Alder BioPharmaceuticals MRNS Marinus Pharmaceuticals MTCR Metacrine XENE Xenon Pharmaceuticals ETNB 89bio PRTA Prothena plc REGN Regeneron Pharmaceuticals NBSE NeuBase Therapeutics ACHN Achillion Pharmaceuticals CRBP Corbus Pharmaceuticals EIGR Eiger Biopharmaceuticals ITMN InterMune MNMD Mind Medicine MRTX Mirati Ther PTI Proteostasis Therapeutics AMAM Ambrx Biopharma American Depositary Shares AXSM Axsome Therapeutics APLT Applied Therapeutics CTNM Contineum Therapeutics, Common Stock NMRA Neumora Therapeutics ACAD ACADIA Pharmaceuticals MLTX MoonLake Immunotherapeutics RARE Ultragenyx THTX Theratechnologies CDTX Cidara Therapeutics GHRS GH Research PLC NRIX Nurix Therapeutics KYMR Kymera Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Sumant Kulkarni (CANACCORD)